NCT Number: NCT00277823
Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Beverly Hills, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Clinical diagnosis of major depressive disorder
- Must be able to swallow tablets
- Must be at least 18 years of age.
Exclusion criteria
- Clinical diagnosis of other psychiatric disorders
- Significant risk of suicide
- Unstable medical conditions.
Treatment and study plan
DVS-SR 100 mg
DrugPlacebo
DrugPrimary outcomes
-
The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS SR versus subjects receiving placebo.
Secondary outcomes
-
Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Important dates
- Study start
- 2006
- Study completion
- 2007
- First posted
- Jan 16, 2006
- Registry last updated
- Dec 28, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
CBT+ for Depression
NCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsTrial of Mirtazapine for Depression in IBD
NCT06309472
Behavior, Behavioral Symptoms
London, United Kingdom
View Trial DetailsExamination of Glutamate and mGluR5 in Psychiatric Disorders
NCT02727972
Behavior, Behavioral Symptoms
New Haven, Connecticut, United States
View Trial DetailsRapid Antidepressant Improvement Secondary to Excitatory Brain Responses
NCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial Details